Acepodia, Inc. (TPEX:6976)
Taiwan · Delayed Price · Currency is TWD 12.30
+0.20 (1.65%)
Apr 17, 2026, 1:38 PM CST
Acepodia Company Description
Acepodia, Inc. operates as a clinical stage biotechnology company.
The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care.
It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; The company is based in Grand Cayman, the Cayman Islands.
Acepodia, Inc.
| Country | Cayman Islands |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Shih-Chia Hsiao |
Contact Details
Address: Ugland House Grand Cayman, KY1-1104 Cayman Islands | |
| Phone | 345 02 2697 6100 |
| Website | acepodia.com |
Stock Details
| Ticker Symbol | 6976 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | KYG0073G1091 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shih-Chia Hsiao Ph.D. | Co-Founder, Chief Executive Officer, President and Chairman |
| Dr. Yuhmin Yang Ph.D. | Co-Founder and Advisor |
| YanDa Lai | Executive Director of Operations |
| Yajun Wang Ph.D. | Chief Technical Officer |
| Jessica Lee M.B.A., M.S. | Head of Business Development |
| Dr. Arthur Foo Ph.D. | Head of Clinical operation |
| Stephanie Hsiao | Secretary |